Today: 21 May 2026
Firefly Aerospace stock wobbles before open after 13% slide as lock-up expiry nears
27 January 2026
1 min read

Firefly Aerospace stock wobbles before open after 13% slide as lock-up expiry nears

New York, Jan 27, 2026, 07:40 EST — Premarket

  • Firefly Aerospace shares tumbled about 13% Monday and barely budged in early trading Tuesday
  • Next week’s lock-up expiry could flood the market with additional shares, traders say
  • Expect the next earnings report in late February

Firefly Aerospace Inc shares remained flat in early premarket trading Tuesday, after plunging sharply the day before. The spotlight now turns to next week’s lock-up expiration, seen as the next critical milestone for investors.

Shares of the space launch company closed at $25.20, down $3.93, a drop of about 13.5%.

That matters since a lock-up agreement stops insiders from offloading their shares for a fixed period post-IPO. When it ends, a sudden flood of shares can hit the market, often pushing the stock price down—even if nothing else has changed.

Firefly’s IPO prospectus revealed that roughly 121,947,950 shares will become available for sale after the lock-up period ends, which is set for 181 days post-prospectus date. The underwriters can also choose to waive these restrictions earlier.

Firefly’s lock-up period expires on Feb. 3, 2026, per Nasdaq’s IPO calendar—a key date that short-term traders should note.

The stock has seen wild swings since Firefly’s 2025 IPO, which Reuters framed as a bet on a revived U.S. space race pulling fresh capital into riskier public ventures.

Sentiment still hinges on hitting key operational goals. Firefly revealed earlier this month that its upcoming Alpha launch, Flight 7, is planned for “in the coming weeks.” A larger “Block II” upgrade is scheduled for the flight after that. Firefly Aerospace

The setup cuts both ways. If insiders stay put or desks see little selling after Feb. 3, the lock-up might barely make a dent. But if shares hit the market in volume, it could spark a vicious sell-off loop.

The lock-up period ending shifts focus to the next earnings report, which Investing.com has slated for Feb. 25.

Stock Market Today

  • Stocks Climb as Oil Prices and Treasury Yields Drop Ahead of Nvidia Earnings
    May 20, 2026, 6:04 PM EDT. U.S. stocks surged with the Dow Jones up 1.31%, S&P 500 gaining 1.08%, and Nasdaq rising 1.54% on May 20, 2026. This followed a sharp decline in oil prices, with WTI crude down 5.66% at $98.26 per barrel, and Brent crude falling 5.63%. Lower oil prices came after reports of progress in Middle East peace talks. Treasury yields eased, with the 10-year yield dropping over 9 basis points, alleviating recent inflation concerns. Market focus shifts to Nvidia's Q1 earnings report, seen as a critical indicator for the AI sector and chip demand. Nvidia shares rose over 1% ahead of results, trading near a 20% gain for the year. Analysts caution that while expectations are muted, the report could influence the broader market sentiment significantly.

Latest articles

Xanadu Jumps 20% After Quantum Selloff, Filing Remains Over XNDU

Xanadu Jumps 20% After Quantum Selloff, Filing Remains Over XNDU

20 May 2026
Xanadu Quantum Technologies’ shares surged 20.4% to $14.13 Wednesday, rebounding after a sharp May decline. The company reported Q1 revenue of $2.83 million and a net loss of $20.6 million, with 43.3 million Class B shares outstanding and a prospectus covering up to 293.7 million more. Other quantum stocks also rose. Xanadu is in talks for up to $285 million in Canadian government support.
MicroAlgo Shares Surge 40% as Quantum Release Drives MLGO Spike

MicroAlgo Shares Surge 40% as Quantum Release Drives MLGO Spike

20 May 2026
MicroAlgo shares surged 39.95% to $5.36 after the company announced a quantum image-processing algorithm, with volume reaching 9.74 million shares versus a 447,270 average. The stock hit $6.87 intraday before slipping to $5.22 after hours. No customer deals, revenue targets, or product launch dates were disclosed. Market cap stood near $66.7 million at the close.
Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

20 May 2026
Immunovant shares jumped 35.3% to $35.56 after reporting 16-week data showing its drug IMVT-1402 produced ACR20, ACR50, and ACR70 response rates of 72.7%, 54.5%, and 35.8% in difficult-to-treat rheumatoid arthritis. Roivant Sciences, its majority owner, rose 14.9%. No new safety signals were reported. The trial enrolled 170 patients, most of whom had failed two prior advanced therapies.
USBC stock jumps in premarket after Uphold, Vast Bank tokenized-deposit deal
Previous Story

USBC stock jumps in premarket after Uphold, Vast Bank tokenized-deposit deal

Dow Jones drops 450 points as UnitedHealth sinks on Medicare rates; confidence slumps
Next Story

Dow Jones drops 450 points as UnitedHealth sinks on Medicare rates; confidence slumps

Go toTop